FirstCare Texas to provide Vermedx Diabetes Information System to health care providers and patients

NewsGuard 100/100 Score

FirstCare Texas has signed a contract with Vermedx, Inc. to provide its patent-pending Vermedx Diabetes Information System (VDIS) for the use of health care providers and patients belonging to First Care Health Plan's health maintenance organization operating in Lubbock, Waco, Abilene, and Amarillo, Texas.

FirstCare CEO Clifford Frank cites the success of the Vermedx Diabetes Information System, as detailed in the March 9 edition of The American Journal of Managed Care. This article describes how Vermedx reduces annual treatment costs by an average of $2,400 per adult patient while improving patient treatment quality. "It's a very cost-effective, quick to implement and easy to operate technology for our providers to add to their repertoire of tools for improving patient satisfaction and enhancing treatment quality," said Frank.

VDIS captures laboratory test results from multiple labs and provides patient-level evidence-based best practices recommendations for care. VDIS also provides quarterly population reports that help clinicians focus on highest risk and out-of-compliance patients in addition to generating automated reminder and alert letters for patients. VDIS is currently being utilized by primary care physicians in managed care and integrated hospital systems in three states, following a successful five-year NIH sponsored clinical trial.

Source:

Vermedx, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Popular diabetes drugs not linked to thyroid cancer risk, study finds